Our results further show positive expression of anti-apoptotic Bcl-2 and p53, followed by significant increase in Annexin V protein expression in mucinous CRC pre-FOLFOX treatment compared with post-treatments and also CRC NOS (p < 0.05). The gene discussed is TP53; the disease is colorectal carcinoma.